Skip to main content
. 2017 Apr 12;8(25):41143–41153. doi: 10.18632/oncotarget.17068

Table 2. Clinical parameters of 11 brain metastases included in the study.

Cases Age bPFS (months) Neurological symtoms Number of brain lesion Site of brain lesion Treatment of brain metastases bOS (months)
1 49 11 NA 1 Parietal lobe Surgery, Chemotherapy 6
2 57 68 Confusional state 1 Occipital lobe Surgery 42
3 70 29 Ataxia 1 Parieto-occipital lobe Surgery WBRT 41
4 70 22 Unilateral symptoms 1 Parietal lobe Surgery Chemotherapy WBRT 6
5 50 18 Headache, vertigo 2 Temporo-occipital lobe, frontal lobe Surgery Chemotherapy WBRT 29
6 70 28 Aphasia, disorientation, dizziness 1 Parietal lobe Surgery, stereotactic radiotherapy 56
7 52 54 NA 1 Frontal lobe Surgery Chemotherapy WBRT 7
8 62 15 Headache, altered walking gait 5 Temporal lobe, frontal lobe, occipital lobe Surgery WBRT 3
9 46 23 NA 1 NA Surgery 3
10 72 18 Ataxia, dysmetria 6 Frontal lobe (the major) Surgery WBRT 7
11 74 25 Vertigo 1 Frontal lobe Surgery WBRT 64

NA: not available; WBRT: Whole Brain Radiotherapy; bPFS: Progression Brain Metastasis Free Survival; bOS: Brain Metastasis Overall Survival.